Sponsored Events

 

Contract-Biotechnology.com is routinely participating in international partnering and conferences. The following event are sponsored by Contract-Biotechnology.com

 


 

Bio-Banking 2018 13-14 June 18 Holiday Inn, Kensington Forum, London, UKhttps://www.smi-online.co.uk/pharmaceuticals/uk/conference/biobanking


This year marks SMi’s 8th annual conference on Biobanking which will take place on 13th & 14th June 2018 in London, United Kingdom. The event will bring together internationally recognised biorepositories, scientific pioneers from pharmaceutical companies, and academics to strengthen current knowledge in biosample management and their research applications. Further, the event will dive into application of novel technologies and security software associated to the protection of data.The conference will aim to broaden the understanding of the ethical and regulatory frameworks, as well as defining the impact that the General Data Protection Regulation (GDPR) will have in 2018. The conference also aims at defining some amongst the most successful applications of biosamples in the market. Speakers are the result of a careful selection of experts in the industry and will include: directors of biorepositories, professionals working in regulatory agencies, drug discovery program directors and legal advisors.Join us in June to take part in cutting-edge discussions through a series of interactive presentations, panel discussions and case-studies addressing all the critical issues regarding the improvement of Biobanking: a market that is expected to reach USD 2.69 Billion by 2022 from USD 1.85 Billion in 2017, at a CAGR of 7.8%.*

 


 

World Cancer Summit 2018 during July 02-03, 2018 in Bangkok, Thailand. The scientific-program of World Cancer Summit 2018 is a rich mix of Interactive Sessions & Sub-sessions, keynote lectures from industry experts, panel discussions, poster competitions and Young Researcher Forum. The conference program will feature well-known and thought-provoking speakers to interactive discussion sessions.

 

Link: https://worldcancer.cancersummit.org/


 

ADMET

Exploring the optimisation of ADMET modelling techniques, preclinical DMPK applications and development of biopharmaceuticals

Location: Holiday Inn Kensington Forum, London, UK     www.admet-event.com/contractbio    

CHAIR: Eric Bloome, Vice President, Global Pre-Clinical Safety Senior Research Fellow, AbbVie

SMi is delighted to announce the 13th annual ADMET conference returning to London on the 9th - 10th July 2018, featuring.  Developments in ADMET and novel technologies determine the properties of a drug candidate in the preclinical stage of drug discovery. Poor ADMET properties are the principal cause for a candidate to fail at any stage of drug development. ADME-Toxicology and Pharmacokinetic studies are the key strategic check-points for pharmaceutical companies to reduce drug discovery cost and minimise production times.  The growing use of ADMET technologies is driving the market growth, which is estimated to reach $14,319.9 Million by 2022, with a CAGR of 10.6% from 2016 to 2022*. The main objective of early prediction of ADME properties of a compound is to increase the success rate of it reaching the development stage.  *Source: http://bit.ly/2hMJcgU  This event is CPD accredited.    

 Early bird offers available!      For speaker line-up, further details and to register, visit the website at www.admet-event.com/contractbio or contact the team at +44(0) 207 827 6000


 

Molecular Diagnostics Evaluate the future of diagnostics for rapid detection and improved clinical outcomes

Conference:  Monday 9th – Tuesday 10th July 2018

Workshops: Wednesday 11th July 2018

Location: Holiday Inn Kensington Forum, London, UK  www.molecular-diagnostics-conference.com/contractbio

Co-Chairs:David Crosby, Cancer Research, UK Hugues Malonne, Director General, DG Post Autorisation, Federal Agency for Medicines and Health Products Belgium.

SMi is proud to announce their 5th Molecular Diagnostics conference. The event will take place in central London on Monday 9th and Tuesday 10th July 2018, along with two half-day post-conference workshops taking place on Wednesday 11th July 2018. The global molecular diagnostics market is forecasted to reach over US$10 billion in the next three years, at a CAGR of 9.1% from 2016 to 2021*. In an ever-evolving universe of molecular diagnostics, it is vital to keep up with emerging and developing technology, products and applications. Furthermore, companies must comply to the constantly change regulatory environment and tackle the challenging process if implementing these regulations.SMi welcomes you to explore the expanding market opportunities, the least diagnostics advancements and regulatory requirements at the 5th Molecular Diagnostics Conference.This event is CPD accredited.

EARLY BIRD-RATES AVAILABLE     For speaker line-up, further details and to register, visit the website at www.molecular-diagnostics-conference.com/contractbio or contact the team at +44(0) 207 827 6000.


September 25-27, 2018 Seville, Spain https://www.biospain2018.org/

 

BIOSPAIN is the largest biotech event organized by a national bioindustry association in Europe and one of the largest in the world by the number of one-to-one meetings (+3.000) and companies participating (+800). 34% of our delegates came from outside of Spain.

BIOSPAIN is organized by ASEBIO, the Spanish Bioindustry Association and each edition is co-organized by a local institution from the host city/region. On the 2018 edition, Biospain is co-organized by the Government of Andalucia through IDEA Agency. 

Some data about the 8th edition of BIOSPAIN held in Bilbao (Spain) were:

 

·         46 investors have attended the eigth edition of Biospain, including Edmond de Rothschild Investment Partners, Forbion, Johnson & Johnson Innovation, Novartis Venture Fund, Ysios Capital Partners, Caixa Capital Risc and Cross Road Biotech. 

·         Biospain 2016 further consolidates its position as the fifth biggest event for business meetings, with 2,970 one-to-one meetings taking place.

·         The event was attended by 1,750 individuals and 701 entities from 29 countries, meaning there was an international presence of 28%.

·         233 exhibitors came together for the event, with more exhibition space than at the previous edition.  

·         84.81% of survey respondents claimed to have identified real business opportunities. 

 


 

Immuno-Oncology Conference 26 – 27 September 2018 London, UK http://www.immuno-oncology-conference.com/contrbioWL

Immuno-Oncology is a fast-paced field with massive potential to deliver successful and durable cancer therapies. SMi's Immuno-Oncology Conference will focus on a few key areas of the field with representation of the whole industry, under each area. These areas will be drawn together to look towards the future of Immuno-oncology and how the field can progress.  In the programme: Targeting immune checkpoints with Humabody VH therapeutics; Recent advances in providing durable disease control with Keytruda as an anti-cancer therapy; Tumour mutation burden and the potential of its use as an indication of treatment choice; Unwanted immunogenicity and functionality testing of immuno-oncology drugs; New techniques, such as the emerging applications of liquid biopsies, in Immuno-Oncology  

  For further details at http://www.immuno-oncology-conference.com/contrbioWL  #immunooncologysmi LinkedIn - SMi Pharma CONTACT: +44 (0)20 7827 6000  ldurneva@smi-online.co.uk


 

  

Orphan Drugs and Rare Diseases Conference 17 – 18 October 2018 London, UK http://www.orphandrugs.co.uk/contrbioWL

SMi’s Orphan Drugs and Rare Diseases Conference bringing together regulatory agencies, pharmaceutical companies, non-profit organisations and orphan drugs developers to construct an agenda that addresses the driving economic factors, policies and issues that will affect the development of orphan drugs globally including commercialisation, policies, reimbursement, and pricing. Discuss the pricing and reimbursement of orphan drugs; Understand the challenges of patient recruitment and patient-centric research; Hear the MHRA’s perspective on benefit-risk assessment in rare diseases; Explore the clinical development of orphan drugs for rare disease; Gain insight into potential synergies between regulators and assessors. Amongst speakers: Carina Schey - University of Groningen; Xavier Ortega – Minoryx; Nigel Nicholls - BioMarin Europe; Yolanda Barbachano – MHRA; Michale Bouskila-Chubb – Healx and many others! Post-conference workshop (19 October) on Working together for HTA in rare diseases - a step too far or the way forward?

Further details at http://www.orphandrugs.co.uk/contrbioWL  #smiorphandrugs CONTACT:+44 (0)20 7827 6000 ldurneva@smi-online.co.uk

International Neurology Conference, December 03-05, 2018, Valencia, Spain
Email: neurology@madridge.com Website: http://neurology.madridge.com/

International Neurology Conference is going to be held during December 03-05, 2018, Valencia, Spain with main theme but not limited to: Neurology and Neurosciences with main focus on Integrative Systems, Central Nervous system and Imaging Techniques.. Neurology-2018 Participants has a wide choice of selection in the scientific sessions which include Neuro technology, Research and Development, Immunology, Neural Engineering, Neurocardiology, Case reports, Pharmacology, Toxicology, Ophthalmology, Physiology, Therapeutics, Nanotechnology applications, Oncology, psychology, Paediatrics, Genetics, Radiology and Imaging studies, Epidemiology etc.. Neurology-2018 conference includes Plenary lectures, Keynote lectures and short courses by eminent personalities from around the world in addition to contributed papers both oral and poster presentations.Targeted Audience:Vice Presidents/Senior Vice Presidents/Executive Vice Presidents, Heads/Leaders/Deans/Senior Professors/Associate Professor/Assistant Professors, Training Institutes, Manufacturing Medical Devices Companies, Clinical Data Management Companies, Machinery Manufacturing Companies, Medical Devices Manufacturing Companies, Neurovaccine Developers and Investigators, Associations and Societies, Business Entrepreneurs, Scientists and Researchers

Abstract Submission Opens:

January 15, 2018 – November 03, 2018

Earlybird Registration:

February 08, 2018 - March 15, 2018

Standard Registration:

March 16, 2018 - December 03, 2018

List of organizing committee members:http://neurology.madridge.com/committee.php We invite Associations/Societies/ Companies to the conference and become a partner and explore your knowledge and grow network with the peers. For any further query please mail us to neurology@madridge.com 



 


To arrange a meeting, please contact us and we will arrange a mutually convenient time.